NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($1.05). The biopharmaceutical company earned $12.43 million during the quarter, compared to analysts' expectations of $13.33 million. View Theravance Biopharma's Earnings History.

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Theravance Biopharma.

4 brokerages have issued twelve-month target prices for Theravance Biopharma's stock. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $35.75 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

News articles about TBPH stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Theravance Biopharma earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Theravance Biopharma.

Theravance Biopharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,640,000 shares, a decrease of 5.4% from the December 31st total of 2,790,000 shares. Based on an average daily trading volume, of 307,900 shares, the days-to-cover ratio is presently 8.6 days. Currently, 6.9% of the shares of the stock are short sold. View Theravance Biopharma's Current Options Chain.

Some companies that are related to Theravance Biopharma include Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), SAGE Therapeutics (SAGE), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), GW Pharmaceuticals PLC- (GWPH) and Progenics Pharmaceuticals (PGNX).

Theravance Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.18%), Campbell & CO Investment Adviser LLC (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma.

TBPH stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma.

TBPH stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Theravance Biopharma.

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TBPH stock can currently be purchased for approximately $26.14.

Theravance Biopharma has a market capitalization of $1.48 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma.

The official website for Theravance Biopharma is http://www.theravance.com/.

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]